Welcome to our dedicated page for Fennec Pharmaceuticals SEC filings (Ticker: FENC), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Fennec Pharmaceuticals Inc. filings document formal disclosures for its commercial specialty pharmaceutical business, PEDMARK® product updates, and Nasdaq-listed common shares. Recent Form 8-K reports cover financial results, scientific presentations and investigator-sponsored studies involving sodium thiosulfate injection, and a license agreement resolving litigation tied to a proposed generic version of PEDMARK.
The company’s proxy materials cover director elections, board composition, executive compensation, equity awards, and shareholder voting matters. Other current reports disclose governance changes, registered common shares with no par value, and exhibits furnished with press releases concerning business, clinical, and product-related developments.
Fennec Pharmaceuticals filed an 8-K to highlight a new clinical research collaboration with the Tampa General Hospital Cancer Institute. The institute is initiating a real-world study of PEDMARK (sodium thiosulfate injection) to evaluate its clinical utility in reducing cisplatin-related hearing loss in adolescent, young adult and adult cancer patients.
PEDMARK is already FDA-approved to reduce ototoxicity in pediatric patients 1 month and older with localized, non-metastatic solid tumors and carries a 2A recommendation from the National Comprehensive Cancer Network for adolescent and young adult use. The study will analyze real-world clinical data and audiology monitoring to help guide future clinical research and quality efforts in managing ototoxicity.
Fennec Pharmaceuticals Inc. reported that its Chief Financial Officer, Robert Andrade, acquired 1,191 common shares as a grant or award at a price of $0.00 per share. A footnote explains these shares were released from restrictions on awards originally granted on 3/31/2023 and 5/16/2024. Following this transaction, Andrade directly owns 243,584 common shares.
FENNEC PHARMACEUTICALS INC. director Rosty Raykov reported multiple equity transactions. On March 2, 2026, he exercised 15,598 stock options at $2.45 per share, receiving the same number of common shares under a 10b5-1 plan adopted on September 19, 2025. He then sold 10,079 common shares at $8.36 per share to cover tax obligations linked to the option exercise. On February 28, 2026, he also acquired 5,208 common shares at no cost as previously awarded shares were released from restrictions. After these transactions, his direct common share holdings were 103,996 shares.
FENC Form 144 reports a proposed sale of 10,079 shares of Common Stock by Rostislav Raykov.
The filing also lists securities sold during the past three months: 10,349 shares on 02/02/2026 for $80,339.29, 10,312 shares on 01/02/2026 for $78,471.23, and 10,000 shares on 12/05/2025 for $75,444.00. The proposed sale is listed as a stock option exercise with a cash transaction.
Fennec Pharmaceuticals Inc. reported new real-world data on its drug PEDMARK® in adults with head and neck cancers. In a multi-institutional retrospective review of 15 adult patients, PEDMARK given at least six hours after cisplatin was feasible, well tolerated, and did not disrupt cisplatin-based treatment delivery.
Investigators observed early signals of hearing preservation, including that most high-risk patients receiving PEDMARK showed no measurable hearing loss during or after treatment, despite frequent baseline impairment. PEDMARK is currently approved in the United States only to reduce the risk of ototoxicity from cisplatin in pediatric patients with localized, non-metastatic solid tumors, and its safety and efficacy in adults with head and neck cancers have not been established.
FENNEC PHARMACEUTICALS INC. Chief Executive Officer Jeffrey S. Hackman acquired common shares through an equity award vesting. On settlement of performance share units that vested on February 18, 2026, he received 13,710 common shares at no stated exercise price. Following this non-cash derivative exercise, his direct ownership increased to 28,710 common shares.
FENNEC PHARMACEUTICALS INC. chief financial officer Robert Andrade reported equity award activity involving both stock options and performance share units. On February 18, 2026, he exercised stock options for 2,450 shares at $4.08 per share, resulting in 215,108 common shares held directly after that transaction. He also acquired 27,285 additional common shares at no exercise price through the settlement of PSUs that vested on the same date, bringing his directly held common shares to 242,393. Following these transactions, his directly held stock options totaled 814,117.
Sonic Fund II, L.P. and related parties report an 8.2% stake in Fennec Pharmaceuticals Inc. As of December 31, 2025, they may be deemed to beneficially own 2,799,959 common shares.
The shares are held directly by Sonic Fund II, L.P., with Sonic GP LLC as its general partner and Lawrence Kam as managing member. Mr. Kam also directly holds shares over which he has sole voting and dispositive power. The filers certify the holdings are not for the purpose of changing or influencing control of Fennec Pharmaceuticals.
Rosalind Advisors Inc. and related investors report a significant passive stake in Fennec Pharmaceuticals Inc. common shares. As of the event date of December 31, 2025, they report beneficial ownership ranging from 9.3% to 9.8% of the company’s common shares, based on 28,116,829 shares outstanding as of November 10, 2025.
Rosalind Master Fund L.P. reports beneficial ownership of 2,613,508 shares, or 9.3% of the class. Rosalind Advisors Inc., as investment adviser, reports 2,746,840 shares, or 9.8%. Portfolio managers Steven Salamon and Gilad Aharon each report beneficial ownership of 2,680,174 shares, or 9.5%, including 66,666 shares over which each has sole voting and dispositive power.
The filing states the securities were acquired and are held in the ordinary course of business and not for the purpose or effect of changing or influencing control of Fennec Pharmaceuticals.
Fennec Pharmaceuticals director Rosty Raykov reported insider transactions involving stock options and common shares. On February 2, 2026, he exercised 15,598 stock options at an exercise price of $2.45 per option under a Rule 10b5-1 trading plan adopted on September 19, 2025, receiving the same number of common shares.
On the same date, he sold 10,349 common shares at $7.76 per share to satisfy tax obligations related to the option exercise. After these transactions, he directly owned 98,477 common shares and 1,602,988 stock options in Fennec Pharmaceuticals.